comparemela.com

Biostar Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Gives Brain Metastasis Drug Orphan Drug Designation

The Food and Drug Administration granted UTD1 an orphan drug designation to treat brain metastases in patients with breast cancer.

Biostar pharmaDrug administrationNational institutes of healthBiostar pharmaceuticalsUnmet needNational institutesEducated patientBreast cancer summitBreast cancerBreast cancer brain metastasisBrain metastasisFda brain metastasis drug

US FDA grants orphan drug designation to Biostar Pharma s utidelone

Biostar Pharma has announced that its pipeline product, UTD1, has received ODD from the US FDA for the treatment of breast cancer BCBM.

Biostar pharma

UTD1 Receives FDA Orphan Drug Designation in Breast Cancer Brain Metastasis

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

Biostar pharmaBiostar pharma incResponse assessmentBreast cancer brain metastasesFda orphan drug designationUtidelone injectable

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic

Biostar pharmaBiostar pharma incBiostar pharmaceuticals co ltdOrphan drug designationThailand business

Utidelone Injectable Granted FDA Orphan Drug Designation for Breast Cancer Brain Metastasis

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

Biostar pharmaUtidelone injectableBreast cancer brainMetastatic brainAccessed march

vimarsana © 2020. All Rights Reserved.